N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
申请人:Wyeth
公开号:US20030027795A1
公开(公告)日:2003-02-06
This invention provides compounds of Formula I having the structure
1
wherein R
1
, R
2
, R
3
, R
4
, W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.